Skip to main content
. 2022 Nov 11;13:1034253. doi: 10.3389/fimmu.2022.1034253

Figure 5.

Figure 5

The pooled risk of any grade (A) and grade ≥3 (B) AEs in patients with R/R B-NHL receiving copanlisib monotherapy or combination therapy with rituximab.